Pfizer seeks Japan’s approval of vaccine for kids aged 5-11
November 10, 2021
TOKYO (Jiji Press) — U.S. pharmaceutical giant Pfizer Inc. and German biomedical company BioNTech SE said Wednesday they have applied to Japan’s health ministry for approval of their COVID-19 vaccine for children aged 5 to 11.
The vaccine has been authorized for emergency use for the age group in the United States. In Japan, it is currently approved for those aged 12 or older.
Clinical trials overseas have found that the vaccine is some 90% effective in preventing COVID-19 in children aged 5-11 with a dosage one-third of the amount given to adults, according to Pfizer.
The vaccine is safe to use for the younger children and side effects among them are comparable with those among adults, the company said.
Children tend to be less affected by the novel coronavirus, but they are encouraged to get shots in the United States to prevent them from transmitting the virus to others.
"Society" POPULAR ARTICLE
-
M6.0 Earthquake Hits Japan’s Tohoku Region; Fukushima, Iwate, Miyagi Prefectures Observe 4 on Japanese Scale With No Risk of Tsunami
-
Shinkansen Services Suspended After Man ‘Searches for Phone’ on Tracks; Disruption Affects About 14,000 Passengers
-
Whaling Mother Ship Built in Japan for 1st Time in 73 Years
-
Tsunami Advisory for Okinawa Lifted at Noon (UPDATE 2)
-
Strong Earthquake Rocks Southern Part of Kyushu; No Risk of a Tsunami
JN ACCESS RANKING
- Japan Lags in Efforts to Gain Value from Human Resources; Govt Working to Increase Usage
- Japan MOF’s Kanda Warns against Yen’s Weakness
- M6.0 Earthquake Hits Japan’s Tohoku Region; Fukushima, Iwate, Miyagi Prefectures Observe 4 on Japanese Scale With No Risk of Tsunami
- Cherry Blossoms Draw Crowd to Tokyo’s Ueno Park; Viewing Season Kicks Off to Slow Start
- Shinkansen Services Suspended After Man ‘Searches for Phone’ on Tracks; Disruption Affects About 14,000 Passengers